clevidipine has been researched along with maraviroc in 1 studies
| Studies (clevidipine) | Trials (clevidipine) | Recent Studies (post-2010) (clevidipine) | Studies (maraviroc) | Trials (maraviroc) | Recent Studies (post-2010) (maraviroc) |
|---|---|---|---|---|---|
| 127 | 19 | 62 | 785 | 124 | 539 |
| Protein | Taxonomy | clevidipine (IC50) | maraviroc (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 3.1 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0014 | |
| C-C chemokine receptor type 5 | Homo sapiens (human) | 0.0044 | |
| C-C chemokine receptor type 5 | Mus musculus (house mouse) | 0.0052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for clevidipine and maraviroc
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |